Industry-Sponsored Research Week

J&J Innovation and Children’s National Health System Launch JLABS @ Washington, DC


By David Schwartz
Published: April 16th, 2019

Johnson & Johnson Innovation LLC and Children’s National Health System are partnering to launch JLABS @ Washington, DC, a 32,000-square foot facility to be located at the new Children’s National Research and Innovation Campus. The co-location of the Research and Innovation Campus with key partners in the areas of public health research, innovation and incubator space is designed to accelerate the translation of discoveries into new treatments and technologies. The new JLABS site will be open to pharmaceutical, medical device, consumer and health technology companies.

The new facility marks the 12th JLABS location, which apply a no-strings-attached model in which entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS facilities have incubated more than 500 companies to date and are currently home to over 330 companies advancing pharmaceutical, medical device, consumer and health technology programs.

“The vision we pursued for this campus required a global innovation partner with a strong commitment to pediatric health and a clear understanding of the next big areas of opportunity for improving human health. We believe the JLABS model is exactly what is needed to help us drive discoveries that are then rapidly translated into new treatments and technologies,” said Kurt Newman, MD, president and CEO of Children’s National.

The new campus will allow the health system to expand its research programs, particularly focusing on pediatric genomic and precision medicine, anchored by the organization’s Center for Genetic Medicine Research and Rare Disease Institute. Its proximity to federal research institutions and agencies, universities, and academic research centers will allow it to leverage the rich area ecosystem to help bolster innovation, according to leaders at the health system.

“JLABS is an integral part of our external innovation strategy designed to help catalyze development of new healthcare solutions globally. We are delighted to launch JLABS @ Washington, DC in this uniquely vibrant and diverse life sciences ecosystem of world-class medical research centers, universities and government entities that can help us address some of the world’s most critical emerging health threats,” said Paul Stoffels, MD, Chief Scientific Officer and Vice Chairman of J&J’s executive committee.

In addition to offering emerging life science companies modular lab units, office space, shared core lab equipment and business facilities, JLABS will link DC-area entrepreneurs with opportunities for funding, third-party services, educational events, and R&D experts from J&J’s medical technology, consumer healthcare product, and Janssen pharmaceutical teams.

“The rich ecosystem of life science innovators across the DC metropolitan area, including the bright minds within both the private and public sectors, provides a network of connectivity that can spark new ideas and propel the next big breakthroughs in science and research to protect and serve our global community,” said Melinda Richter, global head of Johnson & Johnson Innovation – JLABS. “The JLABS’ no-strings-attached model aims to remove the barriers for start-ups by providing the resources they need without taking any equity or intellectual property and encourages collaboration by providing access to the world’s leading experts, executives, and funders to grow their companies.”  

As part of the JLABS @ Washington, DC launch, J&J Innovation is also collaborating with the the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) to develop and maintain a specialized innovation zone that will be dedicated to the advancement of medical countermeasures aimed at minimizing chemical, biological, radiological and nuclear threats, as well as from pandemic influenza and emerging infectious diseases. The innovation zone will provide residency for eligible companies and entrepreneurs focused on reducing those health security threats.

“Through our collaboration with BARDA, we aim to leverage entrepreneurship, bold thinking and a diverse stakeholder ecosystem to help advance new medical countermeasures aimed at protecting both our nation and the citizens of the world,” said Richter. “These threats deserve the exponential strength and ingenuity of the brightest minds and this collaboration will give them the platform to address these threats.”

JLABS also announced the JLABS @ Washington, DC Children’s QuickFire Challenge, which aims to accelerate pediatric-centered healthcare innovation. Innovators with the best ideas, technologies, or solutions that impact pediatric oncology, pediatric surgical care, and influenza will receive up to $150,000 in grant funding, residency at JLABS @ Washington, DC for one year, and mentoring from J&J experts.

Source: PR Newswire

Posted under: University-Industry Engagement Week

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment